Gongwin Biopharm Holdings Co., Ltd.
6617
Rank in Stocks
#12837
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical... Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Share Price
$3.60
Last synced: 2026-11-10
Market Cap
$435.69M
Change (1 day)
9.26%
Change (1 year)
29.39%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Gongwin Biopharm Holdings Co., Ltd. (6617)
Category
Healthcare
EPS for Gongwin Biopharm Holdings Co., Ltd. (6617)
EPS as of June 2026 TTM: $-0.04
According to Gongwin Biopharm Holdings Co., Ltd.'s latest financial reports, its current EPS (TTM) is $-0.04. At the end of 2025 the company had an EPS of $-0.03, a decrease compared to its 2024 EPS of $-0.02.
EPS history for Gongwin Biopharm Holdings Co., Ltd. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.04 | 39.00% |
| 2025 | $-0.03 | 41.55% |
| 2024 | $-0.02 | -21.59% |
| 2023 | $-0.03 | -64.66% |
| 2022 | $-0.07 | 88.16% |
| 2021 | $-0.04 | 26.84% |
| 2020 | $-0.03 | -12.57% |
| 2019 | $-0.04 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $39.05 | -93,745.08% |
US
|
|
| $17.99 | -43,241.49% |
US
|
|
| $7.77 | -18,733.09% |
US
|
|
| $17.99 | -43,241.49% |
US
|
|
| $0.04 | -204.32% |
AU
|
Questions about Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS)
What is Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS)?
Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS) over the last twelve months is $-0.04, as of Jun 2026.
What was Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS) was $-0.03, compared with $-0.02 in 2024.
How has Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS) was highest in 2024 ($-0.02) and lowest in 2022 ($-0.07).
How does Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS) compare with similar companies?
Gongwin Biopharm Holdings Co., Ltd.'s earnings per share (EPS) ($-0.04) is lower than that of all 5 similar companies listed above. The highest among them is McKesson Corporation, with $39.05.